Description: CSL Limited is a biotherapeutics company that develops and delivers biotherapies. The Company's principal activities are research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. Its segments include CSL Behring, Seqirus and CSL Intellectual Property. The CSL Behring segment manufactures, markets and develops plasma therapies (plasma products and recombinants). The Seqirus segment manufactures and distributes non-plasma biotherapeutic products. Seqirus manufactures, sells and distributes a range of vaccines, antivenoms and other pharmaceutical products in Australia and New Zealand. It also manufactures and markets in vitro diagnostic products through Seqirus immunohematology. The CSL Intellectual Property segment is engaged in licensing of intellectual property generated by the Company to unrelated third parties. The Company has facilities in Australia, Germany, Switzerland, the United Kingdom and the United States.
Home Page: www.csl.com.au
CSL Technical Analysis
45 Poplar Road
Parkville,
VIC
3052
Australia
Phone:
61 3 9389 1911
Officers
Name | Title |
---|---|
Mr. Paul R. Perreault B.A. | MD, CEO & Exec. Director |
Ms. Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI | Chief Financial Officer |
Dr. Paul F. McKenzie Ph.D. | Chief Operating Officer |
Mr. Mark Dehring | Head of Investor Relations |
Mr. Gregory Boss B.S., BS(Hons), J.D. | Exec. VP of Legal & Group Gen. Counsel |
Christina Hickie | Sr. Mang. of Communications |
Ms. Elizabeth Walker B.A., M.S. | Exec. VP & Chief HR Officer |
Dr. Karen Etchberger | Exec. VP of Quality & Bus. Services |
Dr. Wilfried Freudenberg | Department Head of Albumin & Immunoglobulins Production |
Ms. Jemimah Brennan | Head of Communications - Asia Pacific |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 43.1034 |
---|---|
Trailing PE: | 39.48 |
Price-to-Book MRQ: | 6.7258 |
Price-to-Sales TTM: | 13.317 |
IPO Date: | |
Fiscal Year End: | June |
Full Time Employees: | 30000 |